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Anticancer drugsThe proteasome inhibitor bortezomib remains the only ubiquitin pathway effector to become a drug
(VELCADE®) and has become a successful treatment for hematological malignancies. While producing a
global cellular effect, proteasome inhibitors have not triggered the catastrophe articulated initially in terms
such as “buildup of cellular garbage”. Proteasome inhibitors, in fact, do have a therapeutic window, although
in the case of the prototype bortezomib it is small owing to peripheral neuropathy, myelosuppression and, as
recently reported, cardiotoxicity [1]. Currently, several second-generation molecules are undergoing clinical
evaluation to increase this window. An alternative strategy is to target ubiquitin pathway enzymes acting at
non-proteasomal sites—E1, E2, and E3, associated with ubiquitin conjugation, and deubiquitylating enzymes
(“DUBs”)—that act locally on selected targets rather than on the whole cell. Inhibitors (or activators, in some
cases) of these enzymes should be developable as selective antitumor agents with toxicity proﬁles superior to
that of bortezomib. Various therapeutic hypotheses follow from known cellular mechanisms of these target
enzymes; most hypotheses relate to cancer, reminiscent of the FDA-approved protein kinase inhibitors
now marketed. Since ubiquitin tagging controls the cellular content, activity, or compartmentation of pro-
teins associated with disease, inhibitors or activators of ubiquitin conjugation or deconjugation are predicted
to have an impact on disease. For practical and empirical reasons, inhibitors of ubiquitin pathway enzymes
have been the favored therapeutic avenue. In approximately the time that has elapsed since the approval
of bortezomib in 2003, there has been some progress in developing potential anticancer drugs that target var-
ious ubiquitin pathway enzymes. An E1 inhibitor and inhibitors of E3 are now in clinical trial, with some ob-
jective responses reported. Appropriate assays and/or rational design may uncover improved inhibitors of
these enzymes, as well as E2 and DUBs, for further development. Presently, it should become clear whether
one or both of the two general strategies for ubiquitin-based drug discovery will lead to truly superior new
medicines for cancer and other diseases. This article is part of a Special Issue entitled: Ubiquitin Drug Discovery
and Diagnostics.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Molecular-based treatment options for cancer patients have
historically consisted of antimetabolites (Gemcitabine/Gemzar®),
topoisomerase poisons (CPT11/Camptostar®), tubulin stabilizers
(Paclitaxel/Taxol®), and, more recently, protein kinase inhibitors
(Imatinib/Gleevec®), with several additional classes undergoing clinical
evaluation (e.g., HDAC inhibitors, phosphatase inhibitors, PARP inhibi-
tors). The era of molecular oncology drugs began in 2001 with the FDA
approval (for chronic myelogenous leukemia) of Gleevec®, an inhibitor
of the protein kinase Bcr-Abl, and, shortly thereafter, of other protein
kinase inhibitors (e.g., Tykerb®, Tarceva®, Nexavar®) for various
malignancies. These kinase inhibitorswere theﬁrst of a new class of anti-
tumor agent (targeted effector) that was developed to deliver efﬁcacyDrugDiscovery andDiagnostics.
+1 610 644 8616.
rn).
l rights reserved.accompanied by a reducednumber and severity of side effects, compared
with those of traditional toxic chemotherapeutic agents. The attractive-
ness of this therapeutic strategy resides in the existence of a multitude
of kinases, each with an identiﬁable function critical to cell growth,
suggesting that selective pharmacologic action is possible. The new, mo-
lecular targeted drugs impact various signaling pathways by post-
translational modiﬁcation—addition (kinases) or removal (phospha-
tases) of a phosphate group to or from a serine, threonine, or tyrosine
of a target protein, resulting most often in activation or deactivation of
an enzyme. A parallel, but more complex post translational modiﬁcation
strategy is afforded by the ubiquitin–proteasome pathway, in which the
76-amino acid protein tag ubiquitin is conjugated to (by sequential ac-
tion of the E1 activating enzyme, E2 conjugating enzyme, and E3 ligase)
or deconjugated from ε-amino groups of lysines of speciﬁc target pro-
teins. Consequences of ubiquitylation/de-ubiquitylation include changes
in cellular half-life (and thus activity) of target proteins, cellular com-
partmentation, and trafﬁcking between cytosol and nucleus or between
the cell membrane and vesicles containing proteases. As in the case of
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numbers of E3 ligases (several hundreds) and DUBs (approximately
eighty). However, in contrast to phosphorylation, the ubiquitin pathway
includes additional levels of complexity. Firstly, a single ubiquitinmay be
conjugated to a target protein or to a ubiquitin already conjugated to a
protein, resulting in poly-ubiquitin chains. Moreover, the poly-ubiquitin
chain linkage may be linear or branched, and may involve one of several
lysines contained in the ubiquitin molecule (e.g., K63, K48, K11). Conse-
quently, the potential for selective binding of a ubiquitin pathway en-
zyme and/or an enzyme inhibitor to the ubiquitylated target protein
must be considered in a more 3-dimensional setting. The ubiquitin-
proteasome pathway offers a third target class—the proteasome itself,
which receives poly-ubiquitylated proteins and degrades them utilizing
various proteolytic activities. During the past two decades, these three
molecular target classes (two that are relatively selective and one that
is nonselective) have been studied and exploited for anticancer drug de-
velopment. In fact, it was the global target, the proteasome, not the
target-selective DUBs or ligases, which produced the ﬁrst positive drug
discovery results and the ﬁrst efﬁcacious ubiquitin pathway drug for
cancer treatment, bortezomib, in 2003.
The following is not meant to be a comprehensive accounting of the
current state of ubiquitin pathway-based drug development, but rather
an impressionistic view of the ﬁeld in 2012 with some necessary cita-
tions. It is focused on cancer, though ubiquitin is relevant to all cell pro-
cesses and thus all pathologies, and it considers in order the proteasome,
the E1–E2–E3 enzyme sequence, and the deubiquitylation reaction as
potential or actual sources of new ubiquitin drugs.
2. Proteasome inhibitors
2.1. Bortezomib: an unanticipated success story
The simple consequence of blocking cellular protein degradation in
the proteasome is the accumulation of ubiquitylated proteins of allTable 1
Proteasome inhibitors currently in clinical development or approved by thsorts, which appears upon ﬁrst consideration to be an intolerable conse-
quence for any cell. The proteasomewas thought of as the cell's garbage
disposal unit, and its blockade assumed to result in a huge excess of
unwanted proteins—a toxic event. On the contrary, however, this global
response has been harnessed to provide antitumor activity againstmul-
tiple myeloma andmantle cell lymphomas in patients, accompanied by
manageable toxicity. In 2003 [1], bortezomib, a dipeptidylboronic acid
that binds reversibly to the β5 subunit of the 20S degradation chamber
of the proteasome and thereby inhibits it, was approved by the FDA for
treatment of relapsed refractory multiple melanoma, following impres-
sive activity in clinical trials [2]. Subsequently, bortezomib was ap-
proved for ﬁrst line treatment of multiple myeloma and for the
treatment of relapsed mantle cell lymphoma [3]. This compound had
been studied extensively during preclinical and clinical development
to elucidate its mechanisms of cytotoxicity and its preference for
tumor vs. normal cells (reviewed in [4]). Because of bortezomib's clini-
cal success, mechanism studies of this drug and other proteasome in-
hibitors have received less attention than the clinical studies, as
bortezomib is active in numerous combinations and may have expand-
ed clinical utility. Nevertheless, details of mechanism are emerging. As
expected, numerous proteins responsible for apoptosis (e.g. p53)
were found to be degraded by the proteasome and it is now clear that
inhibition of proteasome activity leads to apoptosis by sparing these
proteins. Proteasome inhibitors may also induce apoptosis indirectly
by inhibiting NF- κB activation [5], thereby preventing transcription of
various anti-apoptotic proteins. In addition, cellular mechanism studies
have suggested that bortezomib inhibits angiogenesis, which could con-
tribute to its antitumor activity [6], is efﬁcacious in various combination
therapies, and can overcome resistance to traditional cytotoxic thera-
pies [7]. Thus, although bortezomib has a reasonable therapeutic
index, it is a pleiotropic cytotoxic drug (producing peripheral neuropa-
thy and other toxicities commonly associated with chemotherapeutic
agents). Its therapeutic window is very narrow, as dose-limiting toxic-
ities are evident just above the treatment dose. Moreover, due in parte FDA.
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proteasome, resistance to bortezomib is becoming evident [8,9].
2.2. Other proteasome inhibitors in clinical trial
While MLN-9708 and CEP-18770 are both reversible inhibitors like
bortezomib, they offer the potential advantage of oral administration,
which may improve patient experience even though they may not be
superior to bortezomib in therapeutic index or susceptibility to resis-
tance. However, other latter-generation proteasome inhibitors now in
clinical trial (Table 1) may have improved therapeutic index and in
part due to a different mode of binding a diminished tendency to be
compromised by resistance as compared with bortezomib [9]. To ad-
dress these clinical challenges, two proteasome-related strategies have
emerged. The ﬁrst strategy addresses the binding mode. For example,
carﬁlzomib, the next inhibitor scheduled for FDA review, is an irrevers-
ible binder to the chymotrypsin-like β5 site, in contrast to bortezomib,
whichbinds reversibly. The epoxyketonecarﬁlzomib is amore potent in-
hibitor than bortezomib, contributing to an improved therapeutic index.
The second strategy exploits proteasome heterogeneity. In addition to
the classical (“constitutive”) proteasome, which is present in all cells,
some cells contain a second proteasome that differs from the constitu-
tive proteasome in the β1, β2, and β5 catalytic subunits (denoted as
β1i, β2i, and β5i for the immunoproteasome) and contains an 11S regu-
latory particle [10]). Because this second proteasome type can be in-
duced by interferon and generates antigenic peptides for the immune
response, it is known as the immunoproteasome. The heterogeneity
strategy is also exempliﬁed by carﬁlzomib, which inhibits both constitu-
tive proteasomes and immunoproteasomes and overcomes bortezomib
resistance in preclinical models [11]. It is interesting to note that the
most potent experimental immunoproteasome inhibitor, IPSI-001, pref-
erentially targets the β1i subunit of the immunoproteasome and, likeTable 2
Experimental proteasome inhibitors.
4carﬁlzomib, overcomes resistance to bortezomib [12]. An orally bioavail-
able truncated version of carﬁlzomib, ONX 0192, is in Phase I clinical
trial. Another potential means of overcoming resistance to bortezomib
lies in the ability of the irreversible Phase I proteasome inhibitor
NPI0052 which in contrast to bortezomib inhibits the trypsin-like as
well as chymotrypsin-like protease activity [13].2.3. Experimental (preclinical) proteasome inhibitors
Proteasome inhibitors currently in preclinical development are ad-
dressing the issues of therapeutic index (including the need for activity
in a broad spectrum of solid tumors) and resistance in variousways. Fol-
lowing up on an observation in the Goldberg laboratory suggesting that
allosteric interactions among the proteasome subunits may offer addi-
tional therapeutic strategies [14], Kisselev et al. have developed inhibi-
tors that are selective for β1 (caspase-like [15]) or β2 (trypsin-like
[16]) subunits and have shown that trypsin site-selective inhibitors
can sensitize myeloma cells to chymotrypsin-like site inhibitors such
as bortezomib and, in combination with caspase-like site inhibitors, in-
hibit cell growth in the absence of chymotrypsin-like site inhibitors
[16]. Other studies have identiﬁed various known small molecules
(e.g., chloroquine and more potent substituted chloroquines such as
5AHQ) as allosteric inhibitors with clinical potential (reviewed in [10])
(Table 2). It is anticipated that allosteric proteasome inhibitors similar
to these will enter clinical trial within the next few years. Another
class, represented by clioquinol,maywork by bindingmetals that are es-
sential to the proteasome [10]. Finally, deubiquitylating activity resident
in the 19S regulatory portion of the intact proteasome has recently been
identiﬁed as a novel anticancer target using the small molecule b-AP15,
found in a functional screen [17]. This compound selectively inhibited
the deubiquitylating activity of the 19S associated DUBs UCH-L5 and
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a very early but promising class of proteasome inhibitor.
An alternative strategy to targeting the proteasome is to target en-
zymes upstream of the proteasome. In general these enzymes are
considered attractive targets due to the fact that there are multiple
enzymes that modulate ubiquitin conjugation and deconjugation.
Thus, targeting these enzymes offers a greater degree of speciﬁcity
and therefore a reduced potential for side effects. Below we discuss
the current status of small molecule therapeutics that target ubiquitin
conjugation (E1, E2 and E3) and deconjugation (DUBs).
3. E1, E2, and E3 ligase inhibitors
The three enzymes sequentially involved in target protein
ubiquitylation (E1 activating, E2 conjugating, and E3 ligase enzymes)
are currently active targets in anticancer drug discovery [18]. Eight
human E1s, which activate ubiquitin or a ubiquitin-like protein and
transfer it to the E2 conjugating enzyme, are known [19]. Several
dozen E2 enzymes and several hundred E3 ligases are known, al-
though it is not clear howmany of these are potentially therapeutical-
ly relevant. Nevertheless, data presented below support the argument
that selective inhibitors of E1, E2, and E3 enzymes can be found or
designed.
3.1. E1 activating enzyme inhibitors
E1 catalyses the ﬁrst step in the conjugation of ubiquitin or a
ubiquitin-like protein to a target protein—an ATP-dependent covalent
attachment of the ubiquitin or ubiquitin-like protein molecule to its
active site cysteine [18]. An adenosine sulfamate analogue, MLN4924,Table 3
E1, E2, or E3 inhibitors currently in clinical development.inhibits the E1 enzyme responsible for NEDDylation, the covalent addi-
tion of an ubiquitin-like protein, NEDD8, to speciﬁc target proteins includ-
ing SCFSkp2 [20], an E3 ligase linked to cell cycle regulation. In the case of
Skp2, NEDDylation results in pro-growth activation, andMLN4924 is cur-
rently in Phase II clinical trial for hematologic cancers (Table 3). Experi-
mental inhibitors of E1 have also been reported, for example PYR-41, an
irreversible ubiquitin E1 active site binder that enters cells and, while
possibly too reactive to be a clinical candidate, is nonetheless useful
as a tool compound [21] (Table 4).
3.2. E2 conjugating enzyme
Ubiquitin activated by E1 is transferred to a cysteine of the E2
enzyme. E2 then interacts with an E3 ligase, which binds the target
protein and transfers the ubiquitin from the E2 cysteine to a target
protein lysine [18]. Recently a small molecule selective allosteric site in-
hibitor of the E2 enzyme hCdc34, named CC0651, was reported [22].
Cdc34 ubiquitylates p27, among other target proteins, and inhibition
of p27 ubiquitylation and degradation is predicted to prevent tumor
cell cycle progression. Thus, compounds such as CC0651 are in preclin-
ical development as potential anticancer agents.
3.3. E3 ligase
The E3 ligase is responsible for determining which target proteins
are ubiquitylated in concert with E1 and E2; as approximately six
hundred E3 ligases are known, selective inhibition of a given E3 ligase
is likely to affect a limited number of cellular proteins, which under
most circumstances translates to less complicated pharmacology
and potentially limited side effects. The majority of E3 ligases do not
Table 4
Experimental E1, E2, or E3 inhibitors.
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teractions between the charged E2 and the protein substrate. There-
fore, perhaps not surprisingly, the most advanced ligase-based drug
discovery strategy to date has been the development of antagonists
of E3-substrate binding. Attempts to ﬁnd an antagonist of the E3 li-
gase MDM2/HDM2 (HDM2 being the human enzyme) were among
the earliest of these exercises, as MDM2 seemed to be a perfect anti-
cancer target, being responsible for ubiquitylating the tumor suppres-
sor pro-apoptotic protein p53.
The prevailing viewwas that even though fewer than 50% of tumors
possessed functional p53, that number represented a huge patient pop-
ulation that would beneﬁt from therapy directed against MDM2. Inhibi-
tion ofMDM2was one ofmanymolecular oncology strategies employed
in the last 10–15 years tomaximize p53 presence and activity in tumors
([28]; reviewed in [25]), and the two E3 ligase antagonists currently in
clinical trial for cancer, RO5045337 (nutlin-3) and JNJ-26854165
(Table 3), are directed atMDM2, speciﬁcally, at the regulation of its sub-
strate, p53 [23]. Several compounds inhibitingmembers of a family of E3
ligases known as anti-apoptotic proteins (IAPs) have also recently en-
tered clinical trial [24]. These IAPs ubiquitylate proteins that are essen-
tial to apoptosis, eliminating their function and, thus, blocking
apoptosis. Analogs of Smac, a naturally occurring protein that binds to
the IAP, triggering its auto-ubiquitylation, subsume this function and re-
store apoptotic activity. It was speculated in an opinion piece published
in 2005 [26] that the nutlin compounds might not progress to clinical
trial owing to poor animal efﬁcacy and that E3s in general are perhaps
too complex for drug discovery. The fact that 7 years later there are
two MDM2-p53 binding inhibitors (including a nutlin) and seven IAP
antagonists in Phase I/II clinical trial suggests that E3 ligases constitute
a viable, if not the most facile drug discovery area.
In addition to MDM2 and the IAPs, at least nine E3 ligases have
been linked to cancer; most of them, like MDM2, act as oncoproteins
by inhibiting apoptosis or promoting cell cycling, so inhibitors would
be potential anticancer drugs. Although efforts have been made to
ﬁnd inhibitors of these and other E3s (ubiquitylation endpoint), the
search is complicated by the participation of three or four enzymes
in the conjugation reaction [18]. To date no drugs targeting additionalE3 ligases have entered the clinic, although several such inhibitors
have been reported and are useful as tool compounds (Table 4). For
a comprehensive list of potential E3 ligase anticancer targets, see [27].
Thus, for all of the enzymes involved in conjugating ubiquitin to a
protein, small molecule inhibitors are being developed, and, in the case
of E1 and E3 enzymes, are being evaluated in the clinic for treatment of
cancer. While the clinical progression of bortezomib was relatively
rapid, data to date suggest that it may take longer to determine whether
efﬁcacious drugs will come from inhibitors of ubiquitin conjugation.
4. DUB inhibitors
There are approximately eighty known DUBS, proteases that hydro-
lyze isopeptide or α-peptide bonds linking ubiquitin to its target pro-
tein (in some cases another ubiquitin). Many of these have been
validated as targets for cancer and other diseases [27,37,38]. DUBs
serve to recycle ubiquitin monomers to prevent proteasomal degrada-
tion of proteins taggedwith ubiquitin, and to trimubiquitin from tagged
proteins [18,39]. Proteasome-associated DUBs are a very recently de-
scribed class of anticancer target; inhibitors of these enzymes are dis-
cussed above in the Proteasome section. It is the second function–
sparing of target proteins by the removal of conjugated ubiquitin–that
has made DUBs attractive targets for cancer and other diseases [18]. If
the DUB's target protein is beneﬁcial, for example, a tumor suppressor,
DUB activity would be therapeutically advantageous as it would in-
crease the half-life of the beneﬁcial protein. In this case, activators of
the DUB would be therapeutically useful, and there are examples of
well-studied DUBs that would require activation for therapy [27]. It
has been difﬁcult, however, to discover and develop enzyme activators
(as comparedwith receptor agonists), so the opposite strategy has been
more widely pursued—the use of DUB inhibitors to prevent the sparing
of a deleterious target protein (for example, an oncogenic protein) upon
deubiquitylation, ensuring it is degraded, thereby decreasing its cellular
half-life. In the past 10–15 years, tool compounds and/or preclinical de-
velopment candidate small molecule DUB inhibitors have been
reported; these compounds were identiﬁed as inhibitors of several
DUBs and have a range of reported selectivities with respect to other
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inhibitors are given below; their story is a chronicle of the state of
DUB-based anticancer drug development up to the present time
(Table 5).
4.1. Pan-DUB inhibitors
Among the earliest reported DUB inhibitors are cyclopentenone
prostaglandins that induce apoptosis and also increase the cellular
content of poly-ubiquitylated proteins [29]. The latter suggests they
are nonselective DUB inhibitors. A small molecule discovered in
screening for DUB inhibitors, PR-619, is selective for DUBs over
other cysteine proteases, but inhibits all DUBs tested with moderate
potency. PR-619 is cell permeant and thus is useful as a tool com-
pound [30]. More recently, HBX 41,108 which was originally reported
to be a USP7 inhibitor was conﬁrmed to be a non-selective DUB inhib-
itor [31,32].
4.2. UCH-L1 inhibitors
Considerable work has been performed on a series of UCH-L1C-
terminal DUB inhibitors [33]. UCH-L1 is one of the earliest described
DUBs and it has been of therapeutic interest in both neurodegenerative
disease and cancer [40]. Like the pan-DUB inhibitors, these inhibitors
are of moderate potency and enter cells; in addition, many are selectiveTable 5
Experimental DUB inhibitors.for UCH-L1, making them valuable tool compounds for translational
research in cancer and neurodegenerative disease.
4.3. USP7/HAUSP inhibitors
A classic example of the strategy of ablating oncoproteins by inhibiting
the DUBs that protect them fromubiquitylation and degradation is exem-
pliﬁed in the search for suitable inhibitors of USP7/HAUSP, one of the ﬁrst
therapeutically relevant DUBs to be described and arguably the most ac-
tively pursued DUB target in cancer drug discovery today [41–43]. Al-
though USP7, like all DUBS, deconjugates ubiquitin from several target
proteins, inhibition of USP7 promotes the degradation of its primary cel-
lular target, HDM2, resulting in net p53 stabilization and activation
[30,42,43]. Several series of small molecule USP7/HAUSP inhibitors in-
cluding HBX 19,818 and the P005091 analog P050429 have achieved cel-
lular proof of concept (anticipated cellular effects on MDM2 and p53-
dependent protein activities [30,32,34]); some of these compounds are
in preclinical development, but no compound has entered clinical trial.
Other USP7 inhibitors that are not developable are nonetheless being
used as tool compounds.
4.4. Viral DUB inhibitors
DUB inhibitor studies are not restricted to mammalian enzymes.
For example, the competitive small molecule inhibitor, GRL0617
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peptidase Papain-like protease (Plpro) in vitro and in cellular viral
replication assays [36]. Notably the authors were able to obtain a
co-crystal structure of GRL0617 bound to Plpro, which is predicted
to accelerate preclinical development of this series.
Thus, while DUBs with well deﬁned active sites appear to be sim-
pler biochemical targets than E3 ligases, DUB-based anticancer drug
development is proceeding with no more facility than is ligase-
based development, to judge by compounds in the clinic or in late
preclinical development.5. Conclusions
The foregoing illustrates a major paradox in the application of the
enormously complex ubiquitin proteasome pathway to cancer thera-
peutics, which can be articulated in the following question: why has
ubiquitin-based therapy heretofore been more readily achieved by
using a nonselective approach (carpet bombingwith proteasome inhib-
itors) than by employing a selective approach (surgical strike with
highly selective E3 ligase or DUB inhibitors)? A trivial answer may be
that the biochemistry of certain malignancies (proteasome inhibitors
have not yet demonstrated utility over a broad range of tumor types)
makes them hypersensitive to proteasome inhibitor-induced apoptosis,
hence a therapeutic window. An interesting alternative explanation is
that sparing a large number of proteins from degradation by inhibiting
the proteasome ensures that multiple pro-apoptotic, anti-survival ac-
tivities are allowed to proceed, while blocking a single oncogenic DUB
or E3 ligase with an exquisitely selective inhibitor has a limited effect
owing to circumvention by functional redundancy or compensation
by other enzymes. It is possible that inhibitors of limited, rather than ab-
solute selectivity against DUBs or ligases will exhibit improved efﬁcacy,
as in the case of recently approved dual kinase inhibitors [44]. Ongoing
work with new inhibitors of the proteasome and of ubiquitin pathway
enzymes will help to answer these questions.
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